Background and Purpose-Stenting is increasingly used as an adjunct to medical therapy in symptomatic intracranial stenoses. High periprocedural adverse event rates are one of the limitations of endovascular treatment. Data from the INTRASTENT multicentric registry should demonstrate in-hospital complications at the current stage of clinical development of the stent procedure. Methods-Participating centers entered the records of all their consecutive intracranial stent procedures into the database.
I
ntracranial atherosclerosis is the most common cause of cerebral ischemia in the Asian population being detected in 33% of all strokes and in 51% of patients presenting with transient ischemic attack. 1, 2 The proportion of strokes caused by intracranial stenoses is less pronounced in other ethnicities. Nevertheless, intracranial large artery disease proved to be responsible for 8% of strokes in a cohort study performed in Northern Manhattan. 3 In Germany, a large prospective analysis of 4157 patients found intracranial stenosis as the presumed cause of cerebral ischemia in 6.5% of all patients. 4 Therefore, the impact of symptomatic intracranial atherosclerosis is relevant not only in Asian, but also European patients with stroke.
Whereas asymptomatic stenoses seem to bear a relatively low risk, 5, 6 symptomatic intracranial stenoses cannot be regarded as benign lesions. The Warfarin and Aspirin for Symptomatic Intracranial Arterial Disease (WASID) trial showed an overall 1-year risk of stroke of 11% despite medical therapy. 7 For a subgroup of patients with Ͼ70% luminal narrowing, the risk of stroke in the territory of the affected vessel was 19% within the first year. 8 These high rates of stroke recurrence induced the search for alternative therapies.
Intracranial stent placement can be an additional treatment option, but up to now, there is no high-class scientific evidence for the therapeutic effectiveness. INTRASTENT, a European multicentric registry for stent treatment of intracranial stenoses, was supposed to serve as a platform for quality control of participating centers and provided the opportunity to analyze procedure-related complication rates and possible associated risk factors. Our objective here was to report on the technical success and clinical complication rates of stent treatment for symptomatic atherosclerotic stenoses derived from the registry reflecting a "real-world" clinical setting.
Materials and Methods
The INTRASTENT project was approved by the ethics committee of the University of Frankfurt, the local data protection authorities of Hessen, Germany, as well as by the local ethics committees of the participating centers. Eighteen hospitals composed the INTRASTENT study group. The responsible local investigator of each center signed an agreement to include cases consecutively. Any intended treatment of a symptomatic intracranial lesion with a degree of stenosis of Ͼ50% qualified for inclusion in the registry. Prospective inclusion from the time of accession was mandatory. Inclusion of retrospective cases was optional but had to be performed consecutively and completely if done. Clinical follow-up was scheduled at 3 and 6 months. Clinical follow-up data exceeding the 6-month interval could be entered on an optional basis. The decision for performing control angiography was left to the discretion of each center.
Data set entry into the Internet-based registry was done online by the participating centers and was checked for plausibility by a local monitor at the University of Frankfurt.
For the current analysis, we considered all elective stent treatments of symptomatic atherosclerotic lesions with a degree of stenosis of at least 50% measured on digital subtraction angiography images. A degree of stenosis Ͼ70% was regarded as "high grade" and 50% to 70% as "midgrade." We omitted treatments in the setting of an acute vessel occlusion or progressive strokes as well as patients with intracranial dissections and inflammatory stenoses.
Baseline clinical data included patient age, gender, and vascular risk factors. The following vascular risk factors were evaluated: history of arterial hypertension, diabetes mellitus, lipid disorders and coronary artery disease, and current smoking habits. The modified Rankin Scale of each patient was recorded before the intervention and on the day of discharge. Information was to be given about the type of symptoms that led to presentation (transient ischemic attack or stroke).
All treated lesions were characterized by location, degree of luminal narrowing, and morphology.
In the anterior circulation, the intracranial carotid artery was divided into petrous, cavernous, and intradural segments. Of the middle cerebral artery (MCA), only M1 stenoses (common trunk to bifurcation) were included. For the posterior circulation, we considered the extraspinal extradural segment (V3), the intradural segment (V4) of the vertebral artery, and the basilar artery (BA). The degree of stenosis was categorized into midgrade (50% to 70%) and high-grade (Ͼ70%) lesions. Regarding the morphology, we classified short (Ͻ5 mm), moderate (5 to 10 mm), and long (Ͼ10 mm) stenoses. The operator had to judge whether the plaque configuration generated a concentric or eccentric lesion.
Antiplatelet pretreatment was performed according to the local protocol of each center based on a double antiplatelet regimen with aspirin and clopidogrel. The choice of stent was left to the discretion of the operator.
A procedure was counted as a technical failure if stent placement was not possible and/or measurement after the intervention revealed a residual stenosis of Ͼ50%.
All clinical adverse events associated with the procedure had to be reported. For analysis of the severity of complications, we chose 3 categories. The first category contained transient ischemic attacks and nondisabling strokes with a discharge modified Rankin Scale of Ͻ2. Disabling stroke was defined as any stroke leading to a deterioration of the modified Rankin Scale with a score Ն2 at discharge. Imaging was done in case of a clinical event. The choice of imaging method was not prespecified and dependent on the technical resources of each center. Cerebral events were divided in hemorrhagic and nonhemorrhagic. Discrimination between the 2 groups was made by postinterventional imaging. If CT or MRI revealed parenchymal and/or subarachnoid blood, the incident was counted as hemorrhagic irrespective of concomitant or pre-existing brain ischemia.
Statistical analyses of potential risk factors for procedure-related complications were made with the assistance of BiAS.9.02. We used 2 test with Yates correction or Fisher exact test if the number of expected events was Ͻ5 or nϽ20. Statistical tests were performed for all events as well as patient death and disability and hemorrhagic events.
Results
The predefined inclusion criteria were met by 372 patients with 388 stenoses treated in 374 separate procedures from September 1998 until February 2009 (median year of treatment 2007). Of the 388 data sets, 239 were entered retrospectively and 149 prospectively. The median duration of hospitalization was 4 days (range, 0 to 50 days). Table 1 shows the clinical baseline data. The location and morphological characteristics of the treated lesions are summarized in Tables 2 and 3 .
Intracranial stenting was successful in 90.2% of all attempts. Eleven procedures (2.8%) were changed into a balloon angioplasty (percutaneous transluminal angioplasty) alone. Technical failure was not associated with an increased procedure-related event rate (Table 2) .
Patient death or disability occurred 26 times (7%) with a patient mortality rate of 2.2% and 4.8% disabling strokes. The rate of nondisabling events was 5.4% (Table 1) .
Gender, vascular risk factors, and type of presenting symptoms did not influence the periprocedural event rate (Table 1) . Testing for anatomic locations, we did not find significantly increased complication rates for any prespecified site of stenosis. Treating posterior circulation or intradural lesions was not associated with higher complication rates. Also, none of the morphological characteristics of the stenoses showed increased event rates ( Table 2) .
Of all recorded clinical incidents, 13 (3.5%) were hemorrhagic and 12 of those resulted in patient disability or death. The rate of death and disability was significantly increased in brain hemorrhage compared with all other events (Pϭ0.003). Four of the hemorrhagic events were caused by guidewire perforation and 4 were classified as reperfusion hemorrhages. One patient bled after application of intra-arterial thrombolytics for a periprocedural vessel occlusion, another patient bled into a pre-existent infarction, and there was one vessel rupture. In 2 cases, the etiology of the hemorrhage was unknown. Bleeding events occurred significantly more often in MCA stenoses than in any other location (Pϭ0.004; Table 2 ).
Of the remaining 33 cerebral events, 27 were ischemic. Of those, 4 were thromboembolic, 9 were due to occlusion of perforating arteries, 4 were caused by stent thromboses, and 10 were not further classified.
Remarkably, all but one perforator ischemic events occurred after treatment of posterior circulation stenoses and all stent thromboses were located in the anterior circulation.
One severe contrast reaction resulted in a disabling stroke. Five transient cerebral events were not clearly attributable to either ischemia or toxic effects of the contrast agent.
Discussion
The data of the INTRASTENT registry provided a detailed insight into technical success, complication rates, and patient outcomes after intracranial stent treatment in routine practice throughout 18 participating centers and a high number of 372 patients. Therefore, the data represent a "real-world" setting with a relatively broad application of this method.
Technical success according to the predefined criteria was achieved in 90.2% and therefore was slightly lower than in other reported series with technical success rates ranging from 91.7% to 99%. 9, 10 This may in part be due to the fact that some operators preferred to change their strategy into a percutaneous transluminal angioplasty rather than forcing the stent procedure. Percutaneous transluminal angioplasty alone was performed in 2.8% of all attempted treatments.
Clinical complication rates in this registry were 4.8% for disabling strokes and patient mortality was 2.2%. In 5.4% of all treatments, we observed clinical symptoms that were transient or did not lead to relevant functional impairment.
The rate of hemorrhagic cerebrovascular events was 3.5% and cerebral bleeding was associated with a significantly increased rate of death and disability. The high morbidity and mortality in this type of complication may in part be explained by the standard double antiplatelet premedication that probably aggravates hemorrhages and therefore the accompanying clinical symptoms. On the other hand, sufficient platelet inhibition is essential to prevent in-stent thrombosis as a source of ischemic stroke and can therefore not be omitted. The frequency of hemorrhages we observed in the registry was in good agreement with a series from Japan reporting a bleeding rate of 3% after endovascular treatment of intracranial stenoses. 11 We were not able to define a subgroup with an increased risk for procedure-related morbidity and mortality taking into account patient age, gender, vascular risk factors, and presenting symptoms. Therefore, we cannot propose any of these characteristics as a selection criterion for patients considered for intracranial stenting. Within the US Multicenter Wingspan Registry, stroke as a presenting symptom was associated with a higher rate of cerebrovascular complications. This finding could not be reproduced in the European INTRASTENT registry. 12 There was no specific location of stenoses associated with a significantly increased risk of procedure-related morbidity; nevertheless, there was a trend of increased complication rates treating MCA and basilar artery stenoses. An extradural location is often regarded as a "lower-risk lesion" by interventionalists, but the data of the registry do not confirm this assumption. Although overall complication rates, morbidity, and mortality did not differ, we saw some differences in the types of complications occurring at different sites. MCA stenoses were associated with a significantly higher rate of hemorrhagic events. Reaching a stenosis in the MCA can be challenging due to the curved anatomy of the carotid siphon, which could lead to unintentional movement of guidewires carrying the risk of vessel perforation. In addition, all but one ischemic stroke classified as caused by perforator occlusion occurred in the posterior circulation. The mean diameter of perforating branches in the MCA is known to be 472 m and therefore is substantially larger than perforating branches in the basilar trunk and vertebral artery measur- ing 391 m and 243 m, respectively. [13] [14] [15] The size of side branches is a known predictor of antegrade flow after stenting of coronary arteries. 16 Therefore, the smaller average size of the perforating arteries in the posterior circulation might contribute to the higher arterial branch vulnerability in this anatomical location. Data collection within this registry does not allow to draw definitive conclusions regarding the etiology of cerebrovascular *Absolute and relative numbers of technical failure, nondisabling events, disabling events, death, combined death and disability, and hemorrhagic incidents are given for each location separately. We tested every location for frequency of technical failure, all events, death and disability, and hemorrhagic events using 2 test or Fisher exact test with a P value cutoff Ͻ0.05. The frequency of hemorrhagic events was increased treating MCA stenoses ( †Pϭ0.004); all others did not show statistically significant results. We saw a trend for higher complication rates treating MCA and basilar artery stenoses.
ICA, internal carotid artery; V3, extraspinal extradural segment of the vertebral artery; V4, intradural segment of the vertebral artery; BA, basilar artery. *Absolute and relative numbers of technical failure, nondisabling events, disabling events, death, combined death and disability, and hemorrhagic incidents are given for each subgroup separately. We tested every subgroup for frequency of technical failure, all events, death and disability, and hemorrhagic events using 2 test or Fisher exact test with a P value cutoff Ͻ0.05. None of the characteristics showed an increased event rate.
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events because a relevant proportion was not precisely classified, but the results might serve to generate new hypotheses for further studies on different types of cerebral events in intracranial stenting procedures. The length of the stenosis, morphology, and degree of stenosis did not have an impact on all or severe procedurerelated complications. With a morbidity and mortality of 7%, a benefit might exist for patients with high-grade stenoses and a high risk of recurrence on medical therapy alone. In patients with a lesser degree of luminal narrowing, the complication rates did not differ significantly from high-grade stenoses. Assuming a 1-year risk of stroke of 7% to 8% in the subgroup with midgrade stenoses on medical therapy alone, caution should be paid offering these patients intracranial stent treatment, because procedure-related death and disability may outbalance the 1-year stroke risk. Our results imply that treatment should be restricted to high-grade lesions with a higher expected risk of recurrent stroke.
Study Limitations
Data collection in the registry was not purely prospective and the angiographic results and images of intracranial complications were not validated by a core laboratory. Due to the lack of a prespecified treatment protocol regarding premedication, the procedure itself, and postprocedural management of the patients, some important factors influencing patient outcome might have been missed.
This article is about in-hospital complication rates and does not include the 30-day follow-up data. Therefore, adverse events occurring during this period of time were not considered and 30-day morbidity/mortality is probably higher than the in-hospital complication rates reported here.
Conclusion
Patient morbidity and mortality within the INTRASTENT registry was in good agreement with other reported case series and meta-analyses. Because complication rates treating midgrade and high-grade stenoses did not show significant differences, interventional therapy should be confined to highgrade lesions being at high risk for recurrent stroke with medical therapy alone. We were not able to define any risk factors for all-cause procedure-related death and disability taking into account patient age, gender, vascular risk factors, location of stenosis, length of stenosis, and configuration. Complications seem to be rather inherent to the procedure itself than patientdependent. Causes of death and disability were very variable and some anatomic locations seem to be more prone to develop certain types of events. MCA stenoses were significantly more often associated with hemorrhagic stroke than any other location and all but one perforator stroke occurred in the posterior circulation. For future studies, we suggest more detailed and prospective analyses of different types of complications to optimize patient management and to better adapt the material with the aim to substantially reduce the risk of the intracranial stent procedure. 
目前为止，并没有强有力的证据证实其疗效。IN-
TRASTENT 是欧洲一项颅内动脉狭窄支架治疗的多 中心研究，旨在为参与中心的质量控制提供平台， 并提供对手术相关并发症发生率和可能相关的危险 因素进行分析的机会。本文的目的是报告 INTRAS- TENT 研究中症状性颅内动脉粥样硬化性狭窄支架 治疗的技术成功率和临床并发症发生率，以反映该 技术的临床现状。 材料和方法 INTRASTENT 研究由法兰克福大学伦理委员会 和各参与中心的伦理委员会批准通过。法兰克福大 学伦理委员会是德国黑森州地区数据保护的权威机 构。共有 18 家医院参加 INTRASTENT 研究。每个 中心的研究负责者签署协议保证连续纳入病例。任 何有症状性颅内动脉病变狭窄程度 >50% 拟支架治 疗的病例均符合入选标准。研究开始后必须前瞻性 纳入病例，可选择性纳入回顾性病例，但必须是连 续病例并且资料完整。临床随访定于入组后 3 个月 和 6 个月。超过 6 个月后进行选择性的临床随访。 是否复查脑血管造影由各中心决定。 数据集由参与中心通过互联网输入，并由一位 法兰克福大学的监察员进行核查。 为了分析需要，我们认为所有被选择进行支架 治疗的症状性动脉粥样硬化病变在数字减影血管造 影 (DSA) 成 像 上 狭 窄 程 度 至 少 为 50%。 狭 窄 程 度 >70% 被认为是"高度狭窄" ，50%-70% 为"中度狭 窄" 。排除急性血管闭塞或进展性卒中，以及颅内动 脉夹层和炎性狭窄的患者。 基线临床资料包括患者的年龄、性别和血管危 险因素。血管危险因素包括高血压史、糖尿病史、 血脂异常史、冠心病史和吸烟。每位患者支架治疗 前和出院时评价改良 Rankin 评分。临床症状 ( 短暂 性脑缺血发作或卒中 ) 的信息也需要提供。 所有治疗病变按部位、管腔狭窄程度和形态特 点分类。 在前循环，颅内颈动脉被分成岩段、海绵窦段 和 硬 膜 内 段。 大 脑 中 动 脉 (MCA) 只 包 括 M1 段 狭 窄 ( 分叉前主干 )。在后循环，我们将椎动脉分为 椎动脉硬膜外段 (V3)、硬膜内段 (V4) 和基底动脉 (BA)。狭窄程度分为中度狭窄 (50%-70%) 和高度狭 窄 (>70%)。 按形态分为短 (<5 毫米 )、 中 (5 至 10 毫米 ) 和长 (>10 毫米 ) 段狭窄。术者须判断斑块是向心或 偏心性结构。 术前各中心按自己的方案进行阿司匹林和氯吡格 雷的双重抗血小板治疗。 支架的选择由术者自行决定。 手术的技术失败定义为，支架不能被植入和 / 或术后残余狭窄 >50%。 所有与手术有关的临床不良事件都要报告。我 们将并发症的严重程度分为 3 个类别。第一类包括 短暂性脑缺血发作和非致残性卒中 ( 改良 Rankin 评 分 <2 分 )。致残性卒中被定义为病情恶化且出院时 改良 Rankin 评分≥ 2 分的卒中。 若出现临床不良事件， 需进行影像学检查。进行何种影像学检查不预先规 定，取决于每个中心的技术条件。不良事件分为出 血性和非出血性。两者的鉴别由侵入性治疗后的影 像学检查判断。如果 CT 或 MRI 检查显示脑实质和 / 或蛛网膜下腔出血，不良事件被归为出血性，而不 考虑合并或事先存在的脑缺血。 使用 BiAS.9.02 软件对手术相关并发症的潜在 危险因素进行统计分析。我们使用 χ 2 检验和 Yates 校正方法。若预期事件频数 <5 或总频数 <20 则使用 Fisher 精确检验。对包括死亡、残疾和出血性事件 在内的所有的不良事件均进行统计分析。 结果 自 1998 年 9 月至 2009 年 2 月 ( 中位时间 2007 年 )，符合入选标准的患者共 372 例，包括 388 例狭 窄，共进行 374 次支架手术。388 组数据中，239 组 为回顾性， 149 组为前瞻性。 中位住院时间为 4 天 (0-50 天 )。表 1 示临床基线资料。表 2 和 3 总结了接受治 疗的狭窄病变的部位和形态特点。 颅内支架植入成功率为 90.2%。11 次手术 (2.8%) 改行球囊血管成形术 ( 经皮腔内血管成形术 )。技术 失败与手术相关不良事件发生率无关 ( 见表 2)。 26 例 (7%) 患者死亡或发生致残性卒中，死亡 率为 2.2%，致残性卒中发生率为 4.8%。非致残性卒 中发生率为 5.4%( 表 1)。 性别、血管危险因素和临床症状不影响围手术 期不良事件发生率 ( 表 1)。分析病变的部位，未发 现任何特定部位的狭窄能显著增加并发症的发生率。 后循环或硬膜内的病变不会增加并发症的发生率。 此外，没有任何狭窄的形态特征与不良事件的发生 率有关 ( 表 2)。 所有临床不良事件中，13 例 (3.5%) 为出血性， 其中 12 例导致患者残疾或死亡。脑出血的死亡和残 疾率显著高于其他事件 (P=0.003)。出血事件中 4 例 由导丝导致动脉穿孔所致，4 例为再灌注出血，1 例 因围手术期出现血管闭塞行动脉内溶栓导致出血， 另 1 例因之前存在的脑梗死出血，1 例血管破裂， 还有 2 例出血原因不明。MCA 狭窄较其他部位更常 发生脑出血 (P=0.004，表 2)。 其余
